Featured Publications

INOVIO is focused on rapidly bringing to market precisely designed DNA medicines to potentially treat and protect people from diseases associated with HPV, cancer, and infectious diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:

Filter by Category

HPV-Targeted

Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses
Science Translational Medicine — October 2012
Disease TargetCervical DysplasiaProductVGX-3100
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
Molecular Therapy Oncolytics — January 2016
Disease TargetCervical DysplasiaProductVGX-3100
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy
Clinical Cancer Research — January 2018
Disease TargetCervical DysplasiaProductVGX-3100
Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis
BMJ — July 2016
Disease TargetCervical DysplasiaProductVGX-3100
Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis
Vaccines — January 2020
Disease TargetRRPProductINO-3107
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer
Clinical Cancer Research — January 2019
Disease TargetHead & Neck CancerProductMEDI0457
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
The Lancet — September 2015
Disease TargetCervical DysplasiaProductVGX-3100

Immuno-Oncology (Non HPV-Associated)

Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT
Molecular Therapy — November 2017
Disease TargethTERTProductINO-5401
Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity
Cancer Immunology Research — September 2013
Disease TargethTERTProductINO-5401
A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity
Molecular Therapy — February 2017
Disease TargetWT1ProductINO-5401
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens
Molecular Therapy — March 2020
Disease TargetPSAProductINO-5151
Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses
Human Vaccines — January 2011
Disease TargetPSA, PSMAProductINO-5401

Infectious Diseases (Non HPV-Associated)

Synthetic Consensus HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin in HIV Infected Individuals
Molecular Therapy — March 2015
Disease TargetHIVProductPENNVAX-GP
HIV-1 Env DNA Vaccine plus Protein Boost Delivered by EP Expands B- and T-Cell Responses and Neutralizing Phenotype In Vivo
PLoS ONE — December 2013
Disease TargetHIVProductPENNVAX-GP
Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine
Vaccine — September 2011
Disease TargetHIVProductPENNVAX-GP
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers
The Journal of Infectious Diseases — March 2019
Disease TargetEbolaProductINO-4201
Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines
The Journal of Infectious Diseases — October 2018
Disease TargetEbolaProductINO-4201
Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus
Microbes and Infection — December 2018
Disease TargetZikaProductINO-4600
Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization
The Journal of Infectious Diseases — July 2018
Disease TargetZikaProductINO-4600
DNA vaccination protects mice against Zika virus-induced damage to the testes
Nature Communications — June 2017
Disease TargetZikaProductINO-4600
In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine
npj Vaccines — November 2016
Disease TargetZikaProductINO-4600
A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates
Science Translational Medicine — August 2015
Disease TargetMERSProductINO-4700
Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine
Vaccine — May 2018
Disease TargetInfluenza
An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model
Nature Communications — September 2017
Disease TargetPseudamonas
Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus
The Journal of Infectious Diseases — March 2016
Disease TargetChikungunya
Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy
Scientific Reports — July 2015
Disease TargetDengue
IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses
Journal of Hepatology — February 2020
Disease TargetHepatitis CProductGLS-6150
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
The Lancet Infectious Diseases — July 2019
Disease TargetMERSProductINO-4700
Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine — Preliminary Report
The New England Journal of Medicine — October 2017
Disease TargetZikaProductINO-4600
Immunogenicity of a DNA vaccine candidate for COVID-19
Nature Communications — May 2020
Disease TargetCOVID-19ProductINO-4800

dMAb™ (DNA-Encoded Monocolonal Antibodies)

Other Development Candidates

DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity
JCI Insight — April 2019
Disease TargetHER2

Delivery Technology/Proprietary Smart Device